News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CANbridge Life Sciences And EUSA Pharma Form Agreement To Commericalize Caphosol® In China


7/28/2014 9:06:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BEIJING--(BUSINESS WIRE)--CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has entered into an exclusive partnership with EUSA Pharma, a Jazz Pharmaceuticals company (Nasdaq:JAZZ), to commercialize Caphosol® in China. Under the terms of the agreement, CANbridge obtains exclusive rights to commercialize Caphosol in China, where over 3.5 million new cancer cases are diagnosed each year, and there is little in the way of a standard adjunct therapy to treat oral mucositis.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES